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PlasmaAbstract This paper describes the development and validation of an HPLC method for the deter-
mination of protein bound and total lipoic acid in human plasma. The essential steps in the total
lipoic acid assay include reduction of disulfide bridge with tris(2-carboxyethyl)phosphine, derivati-
zation via thiol group with 1-benzyl-2-chloropyridinium bromide and HPLC analysis of
S-pyridinium derivative. Protein-bound lipoic acid is first separated from free lipoic acid with the
use of liquid extraction, converted to its reduced counterpart then processed as total lipoic acid.
The method is reproducible, precise and accurate. The inter- and intraday related standard devia-
tion varied from 1.5% to 11.5% and from 1.8% to 19.6%, respectively, while recovery is in the
range of 80.0–106.0% and 80.4–110.8%, respectively. The mean concentration of total lipoic acid
in healthy donors after supplementation with 600 mg and 1200 mg was 0.67 ± 0.40 lmol L1
(137.6 ± 82.1 lg L1) and 1.57 ± 0.34 lmol L1 (323.34 ± 70.07 lg L1), respectively.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1,2-Dithiolane-3-pentanoic acid (C8H14O2S2), commonly known as
lipoic acid (LA), is a direct and an indirect antioxidant used both
in the prevention and treatment of diseases related to oxidative stress.
During the dynamic transformations taking place in living organisms,
LA is metabolized to some catabolites e.g. dihydrolipoic acid
(DHLA), lipoamide, methyl lipoate and other (Kataoka, 1998).
Moreover, it has been proven that LA forms mixed disulfides not
only with GSH, but also with the cysteinyl sulfhydryl in peptides
(Ishii et al., 2010). To the best of our knowledge humans are supple-
mented by LA but not by DHLA. LA is administered for the treat-traviolet
2 G. Chwatko et al.ment of various diseases, such as cardiovascular, diabetes, neurode-
generative and liver disorders (alcohol-induced damage, heavy metal
intoxication and mushroom poisoning) (Bilska and Włodek, 2005;
Bustamante et al., 1998; Gorazca et al., 2011; Rochette et al., 2013).
Furthermore, LA is used as a nutritional supplement in many coun-
tries. The use of dietary supplements without proper control raises
controversy as they are not drugs, and so do not apply to the rules
of drug control. To clarify the function of LA in biochemical and
clinical practice, its identification and determination especially in
plasma and urine is essential (Borowczyk et al., 2015). However, bio-
logical samples contain a large number of individual compounds,
what leads to difficulties in determination of the analytes. Therefore,
reliable analysis of these samples is a fundamental challenge for
researchers. In an ideal case, no sample preparation would be neces-
sary for the proper analysis of a sample, as every manipulation can
lead to loss of analyte and hence loss of accuracy. Plasma is recog-
nized as the most commonly analyzed biological fluid. In human
plasma, albumin (HSA) is the most abundant protein, that exhibits
a set of quite diverse bio-functions, such as: regulation of plasma
osmotic pressure, the source of amino acids during starvation time,
acting as an antioxidant, as well as binding and transport of endoge-
nous and exogenous compounds (Kawakami et al., 2006). HSA exists
in both reduced and oxidized forms. Reduced form of HSA contains
free thiol group at Cys34, which is able to form mixed disulfides with
low-molecular-mass thiols. Thiols bounding to HSA via disulfide
bond are reversible; thus, HSA can act as specific reservoir of plasma
thiols (Oettl and Stauber, 2007). Since DHLA possesses thiol groups
it can be also efficiently bounded to HSA. For this reason we decided
to elaborate the procedure enabling determination of both free and
protein bounded LA (ProtS-LA).
High separation capacity of the HPLC makes it the preferred tech-
nique for analysis of biological samples. Several HPLC methods which
exploit fluorescence (Haj-Yehia et al., 2000; Niebch et al., 1997; Satoh
et al., 2007; Witt and Ru¨stow, 1998), electrochemical (Khan et al.,
2011a, 2010; Khan et al., 2011b; Teichert and Preiss, 2002, 1995)
and mass spectrometry (Chen et al., 2005; Chng et al., 2010; Ishii
et al., 2010; Montero et al., 2012; Trivedi et al., 2004) detection are
available for quantification of LA and DHLA in plasma. All men-
tioned above detection modes exhibit some advantages and have some
limitations. Mass spectrometry detector is considered as an universal,
highly sensitive and provides additional information concerning the
structure of analytes. On the other hand, high purchase and mainte-
nance costs as well as the necessity of handling by highly qualified staff
results in low popularity of this kind of detection in clinical laborato-
ries. Moreover, for these reasons renewed interest in the classical
HPLC with fluorescence or UV detection as a tool for biological thiols
quantification is observed. Fluorescence detectors are well known for
their high sensitivity and selectivity. Nevertheless, LA does not exhibit
a natural fluorescence; thus, for signal enhancement a derivatization
reaction is usually employed. Electrochemical detectors enable direct
LA determination but suffer from troublesome service of detection.
UV detector is known for its stability, universality and low demand
in terms of maintenance. Since molar absorptivity coefficient of LA
appears to be low, the derivatization reaction is needed when UV
detection is used. To the best of our knowledge, only one paper offers
HPLC-UV method for LA determination in plasma (Ezhilarasi et al.,
2014). In this report, we describe our efforts aimed at the elaboration
of new procedures for the determination of total and protein bounded
in plasma by HPLC with ultraviolet detection.
2. Materials and methods
2.1. Chemicals and reagents
1-Benzyl-2-chloropyridinium bromide (BCPB), a derivatiza-
tion reagent, was synthesized in our laboratory as describedPlease cite this article in press as: Chwatko, G. et al., Determination of lipoic acid
detection. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2earlier (Bald et al., 1996). Chloroform, hydrochloric acid, per-
chloric acid (PCA), sodium hydroxide and tris(hydroxymethyl)
aminomethane (TRIS) were purchased from J.T. Baker
(Deventer, the Netherlands). Acetic acid was purchased from
Chempur (Piekary S´lazskie, Poland). HPLC-grade acetonitrile
(MeCN) and methanol (MeOH) were obtained from Labscan
(Dublin, Ireland). Lipoic acid (LA), dihydrolipoic acid
(DHLA), human serum albumin (HSA), 1-octanol and tris
(2-carboxyethyl)phosphine hydrochloride (TCEP) were pur-
chased from Sigma–Aldrich (St. Louis, USA). Stock standard
solutions were prepared by dissolving an appropriate amount
of LA (final concentration 0.1 mol L1) in 0.2 mol L1 NaOH,
BCPB (0.1 mol L1) and HSA (50 g L1) in water, and TCEP
(0.25 mol L1) in TRIS buffer (pH 9). Stock solutions of LA
and BCPB were kept at 4 C for several days without a notice-
able change of content. TCEP solution was prepared daily.
The working solutions were prepared by dilution with water
as needed.2.2. Sample collection
Blood samples were donated by 17 apparently healthy, ethni-
cally homogenous volunteers dosed with commercially avail-
able LA capsules (600 or 1200 mg of LA) for 30 days.
During the study, no additional medications were allowed
except LA. Blood (2 mL) was drawn, with a tourniquet
applied, into a tube containing EDTA in the morning 1 day
before the first LA dose and 1 day after last LA dose. Blood
was centrifuged under standard conditions (10 min, 1000 g,
within <20 min after collection) and plasma was used for
the determination of LA. Informed consent was obtained from
all volunteers, and this study was approved by the Bioethics
Committee of Regional Chamber of Physicians in Krakow
(127/KBL/OIL) and University of Ło´dz´ (22/KBBN-UŁ/
II/2015). Plasma samples were stored at 78 C until analysis.
On the day of analysis, samples were thawed and processed as
described below.2.3. Preparation of Albumin-Cys34-S-LA
HSA (50 g L1) dissolved in 0.1 mol L1 phosphate buffer pH
7.4 was converted to albumin-Cys34-S-LA (HSA-LA) by incu-
bation with 2-fold molar excess of DHLA or LA at 36.6 C for
24 h. Excess LA was removed from HSA-LA by a quintuple
extraction with chloroform as described in Section 2.5.2.2.4. Separation of protein and LA
Portions of 50 lL of water or 50 g L1 HSA were each placed
in eppendorf tube and spiked with 10 lL of standard solutions
with the increasing amount of LA to provide a concentration
in the range 0.1–20 lmol L1. Next, the mixtures were acidi-
fied with 7.5 lL of 3 mol L1 PCA, vortex-mixed and cen-
trifuged at 12,000g for 5 min. The supernatant was
transferred to new tubes and alkalized to pH 7 by the use of
2.5 mol L1 NaOH, 25 lL of 0.5 mol L1 TRIS buffer (pH
9) and 5 lL of 0.25 mol L1 TCEP were added and vortex-
mixed. After 15 min, 10 lL of 0.1 mol L1 BCPB was added
and the mixture was vigorously shaken by hand for 10 s. Next,in human plasma by high-performance liquid chromatography with ultraviolet
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acidified with 15 lL of 3 mol L1 PCA. The mixture was then
transferred to an autosampler vial and injected (5 lL) into the
HPLC system.
A 50 lL of water or 50 g L1 HSA was spiked with stan-
dard solution of LA (final concentration 10 lmol L1). Next,
25 lL of 0.5 mol L1 TRIS buffer (pH 9) and 5 lL of
0.25 mol L1 TCEP were added, vortex-mixed and allowed
to stand for 15 min at room temperature. Next, 10 lL of
0.1 mol L1 BCPB was added, vigorously mixed, held on
15 min and acidified with 15 lL of 3 mol L1 PCA. At the
end, different volume of MeCN (0–90 lL) or MeOH (0–
80 lL) were added, vortex-mixed and put aside for 15 min, fol-
lowed by centrifugation (5 min, 12,000g). Supernatant was
transferred to an autosampler vial and injected (5 lL) into
the HPLC system.2.5. Recommended analytical procedure
2.5.1. Determination of total LA
Plasma samples (50 lL) were mixed with 25 lL of 0.5 mol L1
TRIS buffer (pH 9) and 5 lL of 0.25 mol L1 TCEP. After
15 min of reduction, 10 lL of 0.1 mol L1 BCPB was added,
then sample was vortex-mixed and kept at room temperature
for 15 min (derivatization reaction). Next, to attain a separa-
tion of LA derivative from protein, 15 lL of 3 mol L1 PCA
and 70 lL of MeCN were added, vortex mixed and put aside
for 15 min, followed by centrifugation (5 min, 12,000g). Super-
natant was transferred to an autosampler vial and injected
(5 lL) into the HPLC system.2.5.2. Determination of protein bound LA
Plasma samples (50 lL) were treated with 5 lL of 3 mol L1
PCA and 100 lL of chloroform and vigorously vortex-mixed
for 10 min. After extraction, the mixture was centrifuged
(5 min, 12,000g) and organic as well as water layers was dec-
anted. The proteins were resuspended with 50 lL of
0.5 mol L1 TRIS buffer (pH 9) and processed according to
the procedure described in Section 2.5.1.2.6. Chromatographic analysis
The analyses were performed using a 1220 Infinity LC Agilent
system consisted of a binary pump integrated with degasser,
autosampler, column oven and diode-array detector. The
whole HPLC system was controlled by OpenLAB CDS
ChemStation Edition software. All separations were achieved
through a Zorbax C-18 (150  4.6 mm, 5 lm) analytical col-
umn (Agilent Technologies). The mobile phase consisted of
2% acetic acid solution, pH 2.36 (component A) and MeCN
(component B). For the determination of LA in plasma, gradi-
ent elution was used: 0–5 min, 10–40% B; 5–6 min, 40–10% B;
6–8 min, 10% B. Flow rate of mobile phase was 1 mL min1 at
25 C. The peak of 2-S-pyridinium derivative of LA was mon-
itored at 321 nm. LA-BCPB peak was identified by compar-
ison of its retention time as well as diode-array spectra,
taken at real time of analysis, with that of the authentic
standard.Please cite this article in press as: Chwatko, G. et al., Determination of lipoic acid
detection. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.22.7. Validation study
2.7.1. Selectivity
Six different LA-free plasma samples, obtained from appar-
ently healthy donors were used to evaluate the selectivity of
the method. This was done by investigating the potential inter-
ferences at the chromatographic peak region for LA derivative
using the recommended procedure and chromatographic con-
ditions described in Sections 2.5.1 and 2.6, respectively. More-
over, the test of peak purity by diode-array detector was
performed.
2.7.2. Intra-day and inter-day variation
The intra-day accuracy and precision were estimated by ana-
lyzing five plasma samples spiked with LA at three different
levels 0.1, 1 and 20 lmol L1. The inter-day precision and
accuracy were evaluated on five consecutive days in a week
at the same LA levels in plasma. The spiked plasma samples
were prepared according to a recommended procedure
described in Section 2.5.1. The results were expressed as the
reproducibility of the recovered amount and determined con-
centration as the mean ± SD and the RSD% calculated from
the data obtained.
2.7.3. Calibration
Total LA: To prepare the calibration standards used to deter-
mine LA in human plasma, portions of 50 lL of blank plasma
were each placed in eppendorf tube and spiked with 10 lL of
standard solutions with the increasing amount of LA to pro-
vide a concentration of 0.1, 0.5, 1, 2, 5, 10 and 20 lmol L1
in plasma. The calibration standards were prepared in tripli-
cate according to recommended procedure described in
Section 2.5.1.
Protein bound LA: To prepare the calibration standards
used to determine ProtS-LA in human plasma, portions of
50 lL of blank plasma were each placed in eppendorf tube
and spiked with the increasing amount of HSA-LA to provide
ProtS-LA concentration of 0.5, 1, 1.5, 2, 2.5 and 3 lmol L1
plasma. The calibration standards were prepared in triplicate
according to recommended procedure described in
Section 2.5.2.
The calibration curves were obtained by least-square linear
regression analysis of relationship between peak areas of the
LA derivative and LA concentrations. The slope of the calibra-
tion curve was used to calculate the LA concentrations in
plasma samples.
2.7.4. Limit of detection and quantification
To investigate the lower limits of detection (LOD) and
quantification (LOQ) LA-free blank plasma samples were
spiked with a decreasing concentration of the standard solu-
tion of LA and subsequently subjected to all steps of the
analytical procedure. The study was repeated until the
signal-to-noise ratio reached 3:1 and 6:1 for LOD and
LOQ, respectively.
2.7.5. Stability experiment
Short-term stability of 2-S-pyridinium derivative of LA in the
final analytical solution was tested. Human plasma was spikedin human plasma by high-performance liquid chromatography with ultraviolet
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processed according to the procedure described in Sec-
tion 2.5.1. Acidified final analytical solution containing MeCN
was stored in the autosampler at room temperature and
injected into the HPLC system without delay and consecu-
tively after 1.5, 3, 4, 7, 10, 13, 16 and 19 h.
Short- and long-term stability of LA in plasma was also
evaluated. Human plasma was spiked with LA (final concen-
tration 20 lmol L1), split into four portions and kept at 24,
4, 20 and 78 C. 50 lL of plasma was assayed according
to procedure described in Section 2.5.1 at time zero and in suc-
cessive intervals.
3. Results and discussion
Utility of BCPB has been proven during determination of low
molecular aminothiols in biological samples (Bald et al., 1996;
Chwatko, 2013; Chwatko et al., 2014; Kus´mierek and Bald,
2009a, 2009b; Sypniewski and Bald, 1996). It has been also
used as an effective derivatization reagent for LA determina-
tion in human urine (Chwatko et al., 2014). This method is
based on the reduction of LA to DHLA, conversion of DHLA
to UV-absorbing BCPB derivative and quantification by
HPLC. The aim of present work was to extend the above
derivatization scheme for the determination of total and
protein-bound LA (ProtS-LA) in human plasma. Importantly,
dedicated to urine analytical scheme cannot be directly applied
for the determination of LA in plasma samples. The main
problem has concerned physicochemical properties of LA
and the presence of proteins in the sample. Therefore, individ-
ual conditions for each step of the analytical procedure were
optimized.
3.1. Sample preparation
Sample preparation influences nearly all of the later assay steps
and for this reason it is critical for unequivocal identification
and quantification of the analytes. DHLA reacts with BCPB
(Fig. 1) within 15 min in water solution (pH 9) to form a stable
thioether, 2-S-pyridinium derivative (LA-BCPB). This stable
derivative has a well-defined maximum at 321 nm. To measure
the total LA (the sum of DHLA, LA and ProtS-LA) it is nec-
essary to cleave disulfide bonds prior to derivatization. Such
approach makes free sulfhydryl groups accessible to BCPB.
For this reason, we used TCEP in TRIS buffer at pH 9, at
room temperature for 15 min. Our results show that both
reduction and derivatization require longer times for plasma
samples than for urine (Chwatko et al., 2014). A crucial step
in plasma sample preparation is LA and DHLA separation
from protein. LA and DHLA are the amphiphilic molecules
having both hydrophilic and hydrophobic fragments and can
specifically interact with the surface of proteins. Several meth-
ods, such as liquid-liquid extraction (LLE) (Chng et al., 2010;
Ezhilarasi et al., 2014; Haj-Yehia et al., 2000; Khan et al.,
2011a, 2010, 2011b; Montero et al., 2012; Niebch et al.,
1997; Satoh et al., 2007; Trivedi et al., 2004; Witt and
Ru¨stow, 1998), solid phase extraction (Khan et al., 2010;
Teichert and Preiss, 2002, 1995) and deproteinization (Chen
et al., 2005; Chng et al., 2010; Khan et al., 2011b) can be uti-
lized for removal of LA from protein. In our study, we testedPlease cite this article in press as: Chwatko, G. et al., Determination of lipoic acid
detection. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2deproteinization procedure and LLE for determination of total
LA and ProtS-LA, respectively.
During acidic deproteinization, plasma proteins markedly
adsorb LA; consequently, the concentration of LA in the solu-
tion is lower than expected. In our study, HSA solutions con-
taining LA in the range 0.5–30 lmol L1 were deproteinized
with PCA and assayed for LA content. We observed a lower
LA concentration in final analytical solutions for HSA samples
compared to standard solution (Fig. 2A). Recovery of free LA
was calculated with the use of the following formula:
Recovery ð%Þ ¼ LA amount in HSA sample
=LA amount in standard solution 100%:
The recovery was found to be between 32.4% and 38.9%,
meaning that more than 60% of free LA adsorbed on HSA.
Similar problem concerned separation of proteins and BCPB
derivative of LA. Our experiments have proven that addition
of MeCN or MeOH to PCA significantly increases LA-
BCPB recovery (Fig. 2B). Moreover, better results were
obtained when the mixture of PCA and MeCN was used. In
this case, the recovery reaches 100% while application of
MeOH and PCA mixture afforded only 76%. Our results are
comparable with those obtained by other investigators for
the mixture of MeCN and metaphosphoric acid (recovery,
98%) (Khan et al., 2011b). Finally, for deproteinization of
plasma samples for determination of total LA the mixture of
PCA and MeCN was used.
Since LA shares structural similarity to the medium chain
fatty acids e.g. octanoic acid it is preferably bounded by sit
II in albumin (Atukeren et al., 2010; Kawakami et al., 2006).
An accurate separation of free LA from proteins is essential
for determination of ProtS-LA in plasma samples because
incomplete removal of free LA causes overestimation of
ProtS-LA. Thus, LLE with chloroform, dichloromethane,
diethyl ether, ethyl acetate or 1-octanol was considered. As
described earlier, dichloromethane, diethyl ether and ethyl
acetate were widely used for LA extraction from plasma.
Unfortunately, one can interpret provided results as inconsis-
tent due to the extraction recoveries in case of dichloro-
methane, diethyl ether and ethyl acetate being in the range
of 87.0–98.4%, 75.0–80.3% and 58.1–90.3%, respectively
(Haj-Yehia et al., 2000; Montero et al., 2012; Khan et al.,
2011b, 2011a, 2010; Trivedi et al., 2004; Witt and Ru¨stow,
1998). Additionally, when chloroform/ethanol mixture was
used for LA extraction from plasma samples better recovery
of the analyte was obtained as compared to the other solvents
used (Montero et al., 2012). Then, we have decided to test
chloroform and 1-octanol as the extraction solvents. Our
results show that both solvents completely extracted free LA
from acidified HSA and plasma samples. Additionally, after
extraction of HSA containing free LA (10 lmol L1) the LA-
BCBP peak in protein fraction was not observed. Due to the
better stability of proteins as well as better separation from
the liquid phases for further experiments chloroform was used.
3.2. Chromatography
Because of unique separation parameters of HPLC technique,
it has frequently been used in the analysis of biological sam-
ples. In order to provide a good performance of the assayin human plasma by high-performance liquid chromatography with ultraviolet
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Figure 1 Determination strategy for estimation of total and protein-bound LA in plasma.
Determination of lipoic acid in human plasma 5the chromatographic conditions were optimized in terms of
mobile phase MeCN and acetic acid concentration as well as
column temperature. As expected, an increase in MeCN con-
tent in the mobile phase from 20 to 30% resulted in decrease
of retention factor from 8 to 1 and simultaneous increase in
peak height from 6 to 32 mAU. The effect of acetic acid con-
centration was tested in a range of 0.5–3%. The retention fac-
tor of LA-BCBP slightly decreased (1.4–1) while peak height
increased (16–40 mAU) with increase of acetic acid concentra-Please cite this article in press as: Chwatko, G. et al., Determination of lipoic acid
detection. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2tion. Temperature of the column in the range of 15–40 C
slightly influenced retention parameters. Based on the results
described above, we have chosen chromatographic conditions
specified in Section 2.6. Chromatographic profiles obtained for
the standard, blank and spiked protein fraction as well as total
LA after supplementation are depicted in Fig. 3. As can be
seen endogenous components do not significantly interfere
with LA-BCBP peak. Under these conditions LA-BCPB is
eluted after 5.49 ± 0.01 min (RSD= 0.18%, n= 10).in human plasma by high-performance liquid chromatography with ultraviolet
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Figure 2 Influence of different conditions to separation of LA
and LA-BCPB from protein. (A) Acid deproteinization of HSA
containing LA in the range 0.5–20 lmol L1; (B) The relationship
between MeCN/MeOH volume and separation of LA-BCPB from
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Figure 3 Representative chromatograms of water standard
solution and plasma samples. (A) Standard water solution of
LA, concentration 15 lmol L1. (B) Profile of plasma obtained
from volunteer before (black line) and after oral administration of
600 mg (red line) and 1200 mg (blue line) of LA with total LA
amounting 0.0 lmol L1, 0.53 lmol L1 (108.3 lg L1) and
2.08 lmol L1 (430.0 lg L1), respectively. (C) Profile of blank
(black line) and spiked (red line) with 3 lmol L1 ProtS-LA
plasma samples. Chromatographic conditions are as described in
the text.
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The method was validated for selectivity, precision, recovery,
linearity, limit of detection and quantitation, and stability
according to the guidelines for analytical methods
(Ravichandran et al., 2010; Wille et al., 2011).
The selectivity of our method was demonstrated by provid-
ing the absence of interfering peaks with a signal obtained for
the analyte. For this purpose, six various blank plasma sam-
ples and plasma spiked with LA were analyzed and the chro-
matograms showed sufficient separation of LA-BCPB from
the matrix components. Furthermore, examination of peak
purity showed that LA-BCBP peak was not attributable to
more than one component.
The accuracy of an analytical method may be defined as the
closeness of the measured value obtained by the method to the
true value, whereas the precision as the degree of agreement
among individual test results obtained by replicate measure-
ments (Ravichandran et al., 2010; Wille et al., 2011). The pre-
cision is expressed as the relative standard deviation (RSD),
while the accuracy as the percentage of analyte recovery and
calculated by expressing the mean measured amount as a per-
centage of the added amount. In our study three concentra-Please cite this article in press as: Chwatko, G. et al., Determination of lipoic acid in human plasma by high-performance liquid chromatography with ultraviolet
detection. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.006
Determination of lipoic acid in human plasma 7tions of LA were tested: one at the LOQ, one near the expected
amount of analyte, and one near the upper boundary of the
standard curve. The intra- and inter-day recovery and preci-
sion values were calculated and are shown in Table 1. The cri-
teria for acceptability of the data included accuracy within
±15% from the nominal values and a precision within
±15% RSD, except for LOQ, where it should not exceed
±20% for accuracy as well as precision (Wille et al., 2011).
Obtained in our study values fulfill these requirements.
The relationship between detector response and LA and
ProtS-LA concentrations was continuous and repeatable,
and was demonstrated using a seven-point and six-point cali-
bration curves, respectively. The calibration curves were linear
in the tested range from 0.1 to 20 lmol L1 and from 0.5 to
3 lmol L1 for total LA and ProtS-LA, respectively. The
equations for the linear regression line were y= 1.295x
+ 0.0726 for total LA and y= 0.330x  0.018 for ProtS-
LA; outliers were not excluded. The coefficients of correlationTable 1 Evaluation of the intra-day and inter-day precision and a
proposed method, n= 5.
LA added (lmol L1) Intra-day
LA found ± SD (lmol L1) RSD (%) Reco
Total LA
0.1 0.11 ± 0.02 19.6 108.9
1.0 1.02 ± 0.04 3.4 102.3
20 22.2 ± 0.40 1.8 110.8
ProtS-LA
0.5 0.40 ± 0.05 12.9 80.4
1.5 1.58 ± 0.25 15.6 105.3
3.0 3.13 ± 0.38 12.1 104.3
Table 2 Concentrations of total LA in human plasma before and a
Gender Age (year) LA concentration
Before suppleme
F 39 n.d.
M 41 0.08a
F 43 n.d.
F 40 n.d.
F 28 n.d.
F 55 n.d.
F 43 n.d.
M 47 0.015a
F 39 0.015a
F 28 n.d.
F 39 n.d.
M 63 n.d.
M 57 n.d.
M 30 n.d.
M 53 n.d.
M 50 n.d.
F 62 n.d.
n.d., not detected.
a Concentration below LOQ.
b Supplementation with 1200 mg of LA processed one year later.
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LA and ProtS-LA, respectively.
The LOD and LOQ for total LA and ProtS-LA were exper-
imentally established to be 0.05 and 0.1 lmol L1 for total LA
and 0.2 and 0.5 lmol L1 for ProtS-LA, respectively. The ana-
lyte response at LOQ level fulfills the criteria for precision and
accuracy (Wille et al., 2011), i.e. precision of 20% and accu-
racy of 80–120%. The LOQ and/or LOD for total LA determi-
nation by this method compare favorably with others’ recently
reported values which were obtained by the HPLC method
with UV detection (Ezhilarasi et al., 2014) and match with
the HPLC method with fluorescence detection (Niebch et al.,
1997). Other HPLC methods for LA determination in plasma
based on fluorescence (Haj-Yehia et al., 2000; Satoh et al.,
2007; Witt and Ru¨stow, 1998), mass spectrometry (Chen
et al., 2005; Trivedi et al., 2004) and electrochemical (Khan
et al., 2011a, 2010, 2011b; Teichert and Preiss, 2002, 1995)
detection have better LOQ and/or LOD than our method.ccuracy for total LA and ProtS-LA in plasma obtained by the
Inter-day
very (%) LA found ± SD (lmol L1) RSD (%) Recovery (%)
0.09 ± 0.01 10.5 91.7
0.93 ± 0.06 6.7 92.9
20.8 ± 0.31 1.5 103.9
0.40 ± 0.05 11.5 80.0
1.64 ± 0.25 15.3 109.4
3.18 ± 0.23 7.4 106.0
fter supplementation with LA.
in lmol L1 (lg L1)
ntation After supplementation
600 mg 1200 mgb
0.16 (33.9) 1.36 (281.0)
0.66 (135.4) 1.26 (260.7)
0.53 (108.3) 2.08 (430.0)
1.08 (223.5) 1.28 (264.1)
1.35 (277.6) 1.54 (318.3)
1.39 (287.8) 1.87 (386.0)
0.18 (36.9)
0.27 (56.5)
0.26 (54.5)
0.57 (118.5)
0.32 (65.0)
0.39 (81.3)
0.51 (105.0)
0.82 (169.3)
0.82 (169.3)
0.89 (182.8)
1.13 (233.6)
in human plasma by high-performance liquid chromatography with ultraviolet
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plasma was tested. Under these temperatures LA in plasma
samples was found to be stable for at least 2, 10 days, 26 weeks
and 6 months, respectively. The residual percentages of LA
after mentioned periods of time were 96.5%, 102.5%, 98.7%
and 103.0%, respectively and indicating no stability problems.
Our stability results correspond to those obtained earlier at 24
(Khan et al., 2011b), 20 (Khan et al., 2011a; Chen et al.,
2005) and 80 C (Trivedi et al., 2004) and are inconsistent
with the study provided by Khan et al. (2010) which demon-
strated that spiked plasma samples were stable for only 1 week
at 80 C. Other examinations have shown that exogenous LA
in plasma samples is stable at 70 C for 6 months (Teichert
and Preiss, 1995). LA-BCPB in final analytical solution con-
taining MeCN was found to be stable at room temperature
for 4 h as the concentration of analyte was found to be
103.6% of the initial concentration.
3.4. Application to authentic plasma samples
The optimized procedure for the determination of total LA
and ProtS-LA was applied to the analysis of plasma samples
of apparently healthy volunteers, 28–63 years old (7 men and
10 women), before and after supplementation. In 14 of the
17 plasma samples collected before taking the drug the LA
levels were below the LOD and in 3 samples below the
LOQ. After oral administration of 600 and 1200 mg of LA,
its concentration in plasma was in the range 33.9–287.8 and
260.7–430.0 lg L1 plasma, respectively (Table 2). Further-
more, in all plasma samples ProtS-LA was not observed.
4. Conclusion
We reported the new HPLC based methodology for determination of
total LA and ProtS-LA in plasma. Since absorption of UV radiation
by LA is low, it was derivatized with BCPB following the reductive
cleavage of the ASASA bond with TCEP. Use of BCPB as derivatiza-
tion reagent enhances the detectability because formed S-pyridinium
derivative exhibits relatively high molar absorptivity coefficient
(e = 1  104 L  mol1 cm1). Analytical figures of merit, demon-
strated during the method validation procedure, justify a conclusion
that present procedure is reliable and robust. It should be emphasized
that established sample preparation procedure allows effective differ-
entiation of ProtS-LA from free LA. Importantly, this solution can
be utilized in other HPLC assays including those coupled with mass
spectrometry or fluorescence detection. Developed method has also
several other advantages over previously published assays. To the best
of our knowledge there is only one other HPLC UV method allowing
LA determination in human plasma (Ezhilarasi et al., 2014) while our
method has better LOQ and LOD. An additional advantage is the
short chromatographic run time and employment of small amount
of reagents (eco-friendly method). In conclusion, the method is suitable
for clinical studies and controlling the use of LA supplements.
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